No Data
No Data
Orgenesis Releases Investor Presentation and Regulatory Update
Express News | Orgenesis Inc: Data Indicate a Potentially Favorable Safety Profile With a Lower Incidence of Cytokine Release Syndrome
Express News | Orgenesis Inc: Top-Line Efficacy and Safety Data From Study Had a Complete Response (Cr )of 82% in Adult Patients and 93% in Pediatric Patients
Express News | Orgenesis Announces Positive Results From a Real-World Study of Org-101 CAR-T Therapy in Patients With Cd19+ Acute Lymphoblastic Leukemia
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients With CD19+ Acute Lymphoblastic Leukemia
Sector Update: Health Care